Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications

  • Authors:
    • Tomohiro Haruki
    • Kohei Shomori
    • Tatsushi Shiomi
    • Yuji Taniguchi
    • Hiroshige Nakamura
    • Hisao Ito
  • View Affiliations

  • Published online on: July 3, 2012     https://doi.org/10.3892/or.2012.1894
  • Pages: 915-922
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cell cycle-related molecules play crucial roles in maintaining genomic stability, and can also serve as biomarkers of cell cycle phase distribution at the same time. In this study, we used multiparameter analysis of various biomarkers to investigate their utility for the evaluation of tumor proliferation activities and the prognosis of patients with small-size lung adenocarcinoma. We performed immunohistochemical analysis using five cell cycle-related biomarkers (MCM7, Ki-67, Geminin, Aurora A and H3S10ph) for 102 surgically resected small-size lung adenocarcinomas. We classified them into three phenotypes based on the dominant cell cycle phase distribution of the tumor cell population, and evaluated whether these phenotypes were associated with clinicopathological factors and survival. Phenotype I (MCM7-negative tumors; n=56) was correlated with high or moderate differentiation and reduced local invasiveness (pleural and lymphovascular invasion) compared with phenotype II (MCM7-, Ki-67- and Geminin-positive tumors; n=23) and phenotype III (MCM7-, Aurora A- and H3S10ph-positive tumors; n=17). Five-year survival rates of phenotypes I, II and III were 89.8, 55.4 and 38.6%, respectively, with a significant difference between them (p<0.01). Multivariate analysis revealed that phenotypes II and III were independent prognostic factors in the 79 patients with stage I lung adenocarcinoma. Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma provided novel insights into the cell cycle phase distribution of dynamic tumor cell populations in vivo; it may be possible to evaluate tumor proliferation activities and patient prognosis more precisely if this analytical procedure is used.
View Figures
View References

Related Articles

Journal Cover

September 2012
Volume 28 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Haruki T, Shomori K, Shiomi T, Taniguchi Y, Nakamura H and Ito H: Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications. Oncol Rep 28: 915-922, 2012
APA
Haruki, T., Shomori, K., Shiomi, T., Taniguchi, Y., Nakamura, H., & Ito, H. (2012). Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications. Oncology Reports, 28, 915-922. https://doi.org/10.3892/or.2012.1894
MLA
Haruki, T., Shomori, K., Shiomi, T., Taniguchi, Y., Nakamura, H., Ito, H."Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications". Oncology Reports 28.3 (2012): 915-922.
Chicago
Haruki, T., Shomori, K., Shiomi, T., Taniguchi, Y., Nakamura, H., Ito, H."Multiparameter analysis using cell cycle biomarkers for small-size lung adenocarcinoma: prognostic implications". Oncology Reports 28, no. 3 (2012): 915-922. https://doi.org/10.3892/or.2012.1894